

Gaia Griguolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6598164/publications.pdf>

Version: 2024-02-01

111
papers

1,700
citations

304743

22
h-index

345221

36
g-index

114
all docs

114
docs citations

114
times ranked

2180
citing authors

#	ARTICLE	IF	CITATIONS
1	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	6.3	97
2	Evolution of HER2-low expression from primary to recurrent breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 137.	5.2	94
3	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
4	The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. <i>Cancer Treatment Reviews</i> , 2016, 46, 9-19.	7.7	84
5	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
6	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020, 11, 385.	12.8	67
7	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. <i>Annals of Oncology</i> , 2019, 30, 921-926.	1.2	64
8	Immune characterization of breast cancer metastases: prognostic implications. <i>Breast Cancer Research</i> , 2018, 20, 62.	5.0	54
9	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.7	52
10	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. <i>EBioMedicine</i> , 2022, 75, 103801.	6.1	47
11	HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	46
12	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. <i>Npj Breast Cancer</i> , 2021, 7, 101.	5.2	44
13	Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. <i>Frontiers in Oncology</i> , 2019, 9, 452.	2.8	43
14	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. <i>British Journal of Cancer</i> , 2014, 111, 25-32.	6.4	41
15	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. <i>Cancer Treatment Reviews</i> , 2020, 88, 102064.	7.7	41
16	Olaparib for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 519-530.	2.4	37
17	Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. <i>Oncologist</i> , 2019, 24, e1055-e1069.	3.7	36
18	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 308-317.	7.0	36

#	ARTICLE	IF	CITATIONS
19	Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage III patients treated with standard therapy. <i>European Journal of Cancer</i> , 2020, 136, 7-15.	2.8	32
20	External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. <i>Breast</i> , 2018, 37, 36-41.	2.2	31
21	Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. <i>Oncologist</i> , 2018, 23, 1289-1299.	3.7	31
22	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1902.	3.7	29
23	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. <i>Npj Precision Oncology</i> , 2021, 5, 23.	5.4	26
24	Phase I trial of the oral smoothed inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 766-772.	2.6	25
25	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. <i>ESMO Open</i> , 2022, 7, 100409.	4.5	25
26	The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8102.	4.1	24
27	Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. <i>ESMO Open</i> , 2022, 7, 100433.	4.5	24
28	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , 2019, 24, 1424-1431.	3.7	22
29	Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 98, 102222.	7.7	21
30	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021, 153, 133-141.	2.8	20
31	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
32	Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. <i>Journal of Neuro-Oncology</i> , 2018, 138, 369-382.	2.9	19
33	BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. <i>Breast</i> , 2019, 47, 77-84.	2.2	19
34	Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 295-302.	2.5	17
35	PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 5843-5851.	7.0	17
36	Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available Evidence and Clinical Implications. <i>Cancer Treatment Reviews</i> , 2021, 102, 102323.	7.7	17

#	ARTICLE	IF	CITATIONS
37	Fat grafting for breast cancer patients: From basic science to clinical studies. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1088-1102.	1.0	16
38	Prognostic impact of proliferation for resected early stage "pure" invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , 2017, 35, 21-26.	2.2	16
39	Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study. <i>Breast Journal</i> , 2020, 26, 1296-1301.	1.0	13
40	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. <i>ESMO Open</i> , 2021, 6, 100099.	4.5	12
41	Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy. <i>JCO Oncology Practice</i> , 2020, 16, e211-e220.	2.9	11
42	Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center. <i>Journal of Women's Health</i> , 2019, 28, 544-550.	3.3	9
43	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	7.0	9
44	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 12.	5.2	9
45	A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. <i>Neuro-Oncology</i> , 2022, 24, 2146-2158.	1.2	9
46	Beyond breast specific "Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. <i>Journal of Neuro-Oncology</i> , 2017, 131, 369-376.	2.9	8
47	First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 297-305.	3.7	8
48	Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. <i>Oncologist</i> , 2020, 25, e1355-e1362.	3.7	8
49	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 625636.	2.8	8
50	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2019, 37, 574-574.	1.6	8
51	Olaparib for advanced breast cancer. <i>Future Oncology</i> , 2020, 16, 717-732.	2.4	8
52	1170 Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials. <i>Annals of Oncology</i> , 2021, 32, S407.	1.2	7
53	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 507-507.	1.6	6
54	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 544-544.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases.. Journal of Clinical Oncology, 2021, 39, 2021-2021.	1.6	5
56	A Case of Hodgkin Lymphoma in a Patient with a History of Bone Pain and an Initial Diagnosis of Chronic Osteomyelitis. Tumori, 2015, 101, e99-e102.	1.1	4
57	Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?. Cancer Treatment Reviews, 2017, 60, 100-108.	7.7	4
58	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. BMC Medicine, 2019, 17, 207.	5.5	4
59	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. Breast, 2020, 50, 56-63.	2.2	4
60	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). Clinical Cancer Research, 2021, 27, 3443-3455.	7.0	4
61	Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors. Annals of Oncology, 2016, 27, vi125.	1.2	3
62	Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors. European Journal of Cancer, 2017, 72, S134.	2.8	2
63	Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial. Annals of Oncology, 2019, 30, v81.	1.2	2
64	ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC). Annals of Oncology, 2019, 30, iii7.	1.2	2
65	Abstract P2-05-20: Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype. , 2017, , .		2
66	Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2020, 38, 582-582.	1.6	2
67	BET inhibitors as potential anticancer agents. Drugs of the Future, 2015, 40, 0381.	0.1	2
68	A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC). Annals of Oncology, 2017, 28, vi27.	1.2	1
69	PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis. Annals of Oncology, 2019, 30, v82.	1.2	1
70	8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT). Annals of Oncology, 2020, 31, S19.	1.2	1
71	4P Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC). Annals of Oncology, 2020, 31, S17.	1.2	1
72	Abstract PS5-14: Gene-expression profiling and response to neoadjuvant endocrine treatment in the phase II LETLOB trial. , 2021, , .		1

#	ARTICLE	IF	CITATIONS
73	4MO_PR HER2-low breast cancer: Evolution from primary breast cancer to relapse. <i>Annals of Oncology</i> , 2021, 32, S23.	1.2	1
74	122P Abemaciclib in HR+/HER2- metastatic breast cancer: A real-world experience. <i>Annals of Oncology</i> , 2021, 32, S73-S74.	1.2	1
75	103P Rate of BRCA1/2 pathogenic variants according to family and personal history of cancer in a large cohort of triple-negative breast cancer (TNBC) patients (pts) younger than 60 years of age. <i>Annals of Oncology</i> , 2021, 32, S400-S401.	1.2	1
76	129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial. <i>Annals of Oncology</i> , 2021, 32, S414.	1.2	1
77	Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.. <i>Journal of Clinical Oncology</i> , 2018, 36, 542-542.	1.6	1
78	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series. <i>Pathology Research and Practice</i> , 2022, 233, 153872.	2.3	1
79	335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors. <i>European Journal of Cancer</i> , 2015, 51, S66.	2.8	0
80	316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors. <i>European Journal of Cancer</i> , 2015, 51, S60.	2.8	0
81	Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study. <i>Annals of Oncology</i> , 2017, 28, vi39.	1.2	0
82	External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases. <i>Annals of Oncology</i> , 2017, 28, v89.	1.2	0
83	CMET-29. HORMONE RECEPTORS STATUS: A STRONG DETERMINANT OF THE KINETICS OF BRAIN METASTASES OCCURRENCE COMPARED WITH HER2 STATUS IN BREAST CANCER. <i>Neuro-Oncology</i> , 2017, 19, vi45-vi45.	1.2	0
84	ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model. <i>Annals of Oncology</i> , 2017, 28, v63.	1.2	0
85	A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC). <i>Annals of Oncology</i> , 2018, 29, viii63.	1.2	0
86	Oncological outcome of fat grafting for breast reconstruction after cancer. <i>Annals of Oncology</i> , 2018, 29, viii81.	1.2	0
87	Heterogeneity of triple negative breast cancer occurring in young women: an immunohistochemical analysis. <i>Breast</i> , 2018, 41, S19.	2.2	0
88	Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched study. <i>Annals of Oncology</i> , 2019, 30, v64-v65.	1.2	0
89	99P Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative breast cancer. <i>Annals of Oncology</i> , 2020, 31, S50.	1.2	0
90	168P Development of a combined clinical model to predict progression-free survival (PFS) in advanced breast cancer (ABC) treated with CDK4/6 inhibitors (CDK4/6i). <i>Annals of Oncology</i> , 2020, 31, S76.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Abstract PS10-02: A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies. , 2021, , .		0
92	212P HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment. Annals of Oncology, 2021, 32, S451.	1.2	0
93	281P Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases. Annals of Oncology, 2021, 32, S486-S487.	1.2	0
94	Locoregional and Locally Advanced Breast Cancer. UNIPA Springer Series, 2021, , 429-466.	0.1	0
95	BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 476-476.	1.6	0
96	Cut-off analysis and prognostic relevance of Ki67 for resected early stage pure invasive lobular breast carcinoma (ILC).. Journal of Clinical Oncology, 2016, 34, 544-544.	1.6	0
97	Abstract P1-12-06: Factors related to the prognosis of breast cancer patients after the development of brain metastases. , 2017, , .		0
98	First prospective multicenter Italian study on the impact of the 21-Gene Recurrence Score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients.. Journal of Clinical Oncology, 2017, 35, e12038-e12038.	1.6	0
99	A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC).. Journal of Clinical Oncology, 2017, 35, 539-539.	1.6	0
100	Abstract P1-17-04: Clinical presentation and outcome of leptomeningeal metastasis in patients with breast cancer in relation to histology and tumor subtypes. , 2018, , .		0
101	Abstract P6-18-24: Lapatinib-based therapies after pertuzumab and/or T-DM1 for HER2+ metastatic breast cancer patients. , 2019, , .		0
102	Abstract P6-17-05: Independent validation of a combined biomarker based on the PAM50 HER2-enriched subtype and ERBB2 mRNA levels following HER2 blockade without chemotherapy in the PerELISA phase II trial. , 2019, , .		0
103	Abstract P4-08-04: PD-L1 expression and prognosis in triple negative breast cancer (TNBC): An analysis of 265 patients (pts) treated with standard therapy for stage I-III disease. , 2019, , .		0
104	Abstract P6-17-08: Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy. , 2019, , .		0
105	Abstract P6-17-07: Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer. , 2019, , .		0
106	Abstract P5-06-14: Integrating CD8, FOXP3 and PD-L1 expression in prognostic models for triple negative breast cancer (TNBC): An analysis of 265 patients treated with standard therapy for stage I-III disease. , 2020, , .		0
107	Abstract P5-06-12: Validation of residual proliferative cancer burden (RPCB) as a predictor of long-term outcome following neoadjuvant chemotherapy in hormone-receptor positive/HER2 negative breast cancer patients. , 2020, , .		0
108	Immune microenvironment profiling of breast cancer brain metastases using multiplex immunofluorescence.. Journal of Clinical Oncology, 2020, 38, 2526-2526.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Abstract P3-08-05: Impact of estrogen receptor levels on outcome in triple negative breast cancer patients treated with (neo)adjuvant chemotherapy. , 2020, , .		0
110	Abstract P2-12-04: Characterization of gut microbiome composition in triple negative breast cancer patients treated with neoadjuvant chemotherapy. Cancer Research, 2022, 82, P2-12-04-P2-12-04.	0.9	0
111	Abstract PD4-01: Response according to revised RANO criteria is associated with overall survival in breast cancer patients with leptomeningeal metastasis. Cancer Research, 2022, 82, PD4-01-PD4-01.	0.9	0